Investigating future therapies
Our scientists are committed to developing new therapies for patients with serious genetic diseases that are not well managed with current treatments.
Developing these novel genomic therapies requires years of laboratory research and clinical testing to evaluate their safety and efficacy. Volunteers who enroll in clinical trials help Sangamo researchers understand the potential benefits and risks of these investigational therapies in humans. Investigational therapies must pass through three phases of clinical before they can be approved for medicinal use.
Sangamo is conducting several clinical trials to evaluate the safety, tolerability and potential efficacy of its novel genomic therapies for rare blood and lysosomal storage disorders. Please visit the clinical study websites below or go to clinicaltrials.gov to learn more about our ongoing clinical trials.
Inherited Metabolic Diseases
Legacy Clinical Research